Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasinezumab in Early Parkinson's Disease
NCT04777331Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- May 2021
- Primary completion
- Sep 2024
- Countries
- 9
01
Overview
A Phase 2 trial of prasinezumab in Parkinson's disease (PD), sponsored by Roche. Started May 2021; status: active, not recruiting.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04777331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777331.